Moreover, ABCG2 protein overexpression in concurrence with FLT3-ITD mutation identifies a subgroup of AML patients with significantly worse prognosis (Tiribelli et al., 2011). The gene discussed is ABCG2; the disease is acute myeloid leukemia.